Nabiximols INN: Tetrahydrocannabinol Botanical Drug Substance [1]
Chemical structures of tetrahydrocannabinol (top) and cannabidiol (bottom)
Combination of
Tetrahydrocannabinol
Cannabinoid
Cannabidiol
Cannabinoid
Clinical data
Trade names
Sativex
Routes of administration
Oromucosal spray
ATC code
N02BG10 (WHO)
Legal status
Legal status
AU: S8 (Controlled drug)
In general: ℞ (Prescription only)
Identifiers
CAS Number
56575-23-6N
PubChem CID
44148067
UNII
K4H93P747O
CompTox Dashboard (EPA)
DTXSID40972015
NY (what is this?)(verify)
Canadian packaging of a case of Sativex vials
Nabiximols (USAN,[2] trade name Sativex) is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals.[3][4] In 2019, it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract.[5][6] Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.
In 2003, GW Pharmaceuticals partnered with Bayer to market the drug under the brand name Sativex. In 2011, GW licensed the rights to commercialise nabiximols to Novartis for Asia (excluding China and Japan), Africa and the Middle East (excluding Israel).[7]
^"DDrare: Database of Drug Development for Rare Diseases". ホーム | DDrare (in Japanese). 2016-12-28. Retrieved 2024-03-23.
^"Statement on a non-proprietary name" (PDF). United States Adopted Names Council.
^"Nabiximols". UK Medicines Online.[permanent dead link] Page accessed Feb 3, 2016
^"Sativex (nabiximols) - factsheet". Multiple Sclerosis Trust. October 2014.
^Itin C, Barasch D, Domb AJ, Hoffman A (May 2020). "Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol". International Journal of Pharmaceutics. 581: 119276. doi:10.1016/j.ijpharm.2020.119276. PMID 32243971. S2CID 214785913.
^Itin C, Domb AJ, Hoffman A (October 2019). "A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states". Expert Opinion on Drug Delivery. 16 (10): 1031–1035. doi:10.1080/17425247.2019.1653852. PMID 31393180. S2CID 199505274.
^"GW signs Sativex cannabis-based drug deal with Novartis". The Telegraph. 11 April 2011. Retrieved 12 July 2012.
Nabiximols (USAN, trade name Sativex) is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is...
pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative...
bladder, and other symptoms. Nabiximols (as Sativex) is available as a prescription drug in Canada. In 2021, nabiximols was approved for medical use in...
Cannabis tinctures are used in the production of specific extracts, like nabiximols. Cannabis tincture appeared in the United States Pharmacopoeia until 1942...
in the liver as well as in the intestines by cytochrome P450 enzymes. Nabiximols (brand name Sativex), an oromucosal spray made of a complex botanical...
excretion = urine (55%). Fibromyalgia. As per duloxetine, plus hypertension. Nabiximols Contains cannabidiol and dronabinol in roughly equal concentrations. As...
prominent within the medical industry. THC is also an active ingredient in nabiximols, a specific extract of Cannabis that was approved as a botanical drug...
Global Information
(what is this?) (verify)
